FDA Approves Keytruda (pembrolizumab) for Treatment of Unresectable or Metastatic Melanoma
FDA approves new drug Keytruda for advanced skin cancer.
The FDA has approved Keytruda, a PD-1-blocking antibody, for the treatment of patients with unresectable or metastatic melanoma. This approv…
FDA approves Keytruda to treat advanced skin cancer that cannot be removed by surgery or has spread to other parts of the body.
Systematic review examines HIF-1α role in digestive system inflammation and cancer
Could a single protein be fueling both gut inflammation and cancer?
A systematic review synthesizing existing literature found HIF-1α contributes to pathogenesis of inflammatory digestive diseases and promote…
A single protein called HIF-1α may be driving both gut inflammation and digestive cancers while helping tumors resist drugs and evade the im…
Case report: Orelabrutinib-rituximab with intravitreal methotrexate shows response in primary vitreoretinal lymphoma
Can a new drug combination help treat a rare eye cancer?
A case report with literature review describes one patient with primary vitreoretinal lymphoma (PVRL) treated with orelabrutinib and rituxim…
A new drug combination improved vision and controlled tumors in a patient with a rare eye cancer, with no reported side effects.
Case report describes complete remission in PDTC with combined radiotherapy and chemotherapy
Case report describes complete remission in advanced thyroid cancer patient after combined treatment
A case report and literature review examined a 55-year-old male with advanced poorly differentiated thyroid carcinoma (PDTC). The patient ac…
A 55-year-old man with advanced thyroid cancer achieved complete remission after combining local radiotherapy and intravenous chemotherapy.
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC.
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
PARPi combinations show no significant clinical improvement in adult patients with glioblastoma.
PARPi drugs show limited benefit for glioblastoma due to brain barriers
This systematic review evaluated poly-ADP-ribose polymerase inhibitors (PARPi) combined with standard therapy for adult patients with gliobl…
A systematic review examined PARP inhibitors used with standard treatments for adult glioblastoma patients. The analysis found that these dr…
DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
Breath-hold technique reduces radiation dose to heart during breast cancer treatment
A meta-analysis of 11 studies in left-sided breast cancer patients treated with VMAT found deep inspiration breath hold (DIBH) reduced mean …
Holding a deep breath during radiation therapy consistently lowers the dose to the heart, lungs, and other organs for left-sided breast canc…
Multiphasic CT-based deep learning model predicts early HCC recurrence after liver transplantation
New AI model shows promise for predicting early liver cancer recurrence after transplant
This retrospective cohort study evaluated a multiphasic CT-based multimodal deep learning (MD DL) model in 147 liver transplant recipients. …
A new AI tool using CT scans and lab data predicts early liver cancer return after transplant with high accuracy in past patient records.
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration. Compared to hi…
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Radiomics models predict IDH mutation status and survival in glioma patients across discovery and validation cohorts.
Can scans predict glioma risks without surgery? New models show promise but need more proof.
This multicenter cohort study evaluated radiomics-based machine learning models in 638 glioma patients to predict isocitrate dehydrogenase (…
Computer scans can spot dangerous brain tumor patterns without surgery, but accuracy drops when tested on new patients, so doctors still nee…
CADe Systems Show Variable Improvements in Adenoma Detection During Colonoscopy in Meta-Analysis
AI tools help doctors spot more colon polyps during routine colonoscopies
A systematic review and network meta-analysis of 48 RCTs involving 38,986 patients found that computer-aided detection (CADe) systems improv…
New AI tools help doctors spot more colon polyps during routine colonoscopies, potentially lowering the chance of missing small, flat growth…